| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/18/2012 | EP2407786A1 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer |
| 01/18/2012 | EP2407556A1 Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | EP2407545A1 Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites |
| 01/18/2012 | EP2407536A1 ADP-ribosyl transferase fusion variant proteins |
| 01/18/2012 | EP2407478A1 New cyclotetrapeptides with pro-angiogenic properties |
| 01/18/2012 | EP2407473A2 Method for producing phosphorus-containing compounds |
| 01/18/2012 | EP2407462A1 Substituted chroman derivatives, medicaments and use in therapy |
| 01/18/2012 | EP2407173A1 Method and compositions to induce apoptosis of tumoral cells expressing SHH |
| 01/18/2012 | EP2407165A1 Antioxidant agent |
| 01/18/2012 | EP2407164A1 Copper II complexes of phenanthroline and their use in cancer treatment |
| 01/18/2012 | EP2407161A1 An antitumoral combination comprising ombrabulin and bevacizumab |
| 01/18/2012 | EP2406389A1 Methods and compositions for cell-proliferation-related disorders |
| 01/18/2012 | EP2406302A1 Multifunctional contrast agent using biocompatible polymer and preparation method |
| 01/18/2012 | EP2406290A2 Antigen presenting cell targeted cancer vaccines |
| 01/18/2012 | EP2406289A2 Antigen presenting cell targeted anti-viral vaccines |
| 01/18/2012 | EP2406286A2 Anti-cd40 antibodies and uses thereof |
| 01/18/2012 | EP2406272A1 N-hydroxy c29-amide derivatives of oleandrane |
| 01/18/2012 | EP2406266A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
| 01/18/2012 | EP2406263A1 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof |
| 01/18/2012 | EP2406262A1 Prodrug forms of kinase inhibitors and their use in therapy |
| 01/18/2012 | EP2406261A1 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-one derivatives, method for preparing same, and therapeutic uses thereof |
| 01/18/2012 | EP2406259A1 Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
| 01/18/2012 | EP2406255A1 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| 01/18/2012 | EP2406244A2 Estrogenic compounds and their methods of use |
| 01/18/2012 | EP2406222A1 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 01/18/2012 | EP2406206A1 Tetrahydronaphthalen-2-ol derivatives |
| 01/18/2012 | EP2405944A1 Prodrugs |
| 01/18/2012 | EP2405941A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 01/18/2012 | EP2405916A2 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| 01/18/2012 | EP2405908A1 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| 01/18/2012 | EP2405907A1 Treatment of pancreatic cancer |
| 01/18/2012 | EP2405772A1 Covalent milk protein/isothiocyanate complexes |
| 01/18/2012 | EP2405750A1 Combination therapy with thiocolchicine derivatives |
| 01/18/2012 | EP2327413A9 Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| 01/18/2012 | EP1941887B1 Metallo-fullerenols and its application in preparation of medicines for inhibiting the growth of tumour |
| 01/18/2012 | EP1893196B1 Diarylhydantoin compound |
| 01/18/2012 | EP1726310B1 Drug for cancer therapy |
| 01/18/2012 | EP1617873B1 Treatment of multi-drug resistant tumours by a conjugate of mitomycin C |
| 01/18/2012 | EP1546138B1 Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes |
| 01/18/2012 | EP1456385B1 Growth hormone fusion protein |
| 01/18/2012 | EP1454138B1 Immunocytokines with modulated selectivity |
| 01/18/2012 | EP1429844B1 Conjugate of perphenazine and gaba and uses thereof |
| 01/18/2012 | EP1390075B1 Chemotherapeutic induction of egr-1 promoter activity in gene therapy |
| 01/18/2012 | EP1292709B1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 01/18/2012 | EP1257822B1 Her-2 binding antagonists |
| 01/18/2012 | EP1053256B9 Antibodies to death receptor 4 (dr4) and uses thereof |
| 01/18/2012 | EP1013661B1 2'-O,4'-C-methylene bicyclonucleosides |
| 01/18/2012 | CN1951962B Polypeptide for preparing antineoplastic antibody and its uses |
| 01/18/2012 | CN102325905A Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | CN102325796A Anti-human [alpha]9 integrin antibody and use thereof |
| 01/18/2012 | CN102325788A Cancer-targeting peptides and uses thereof in cancer therapy |
| 01/18/2012 | CN102325780A 6-phenyl-2-[((piperidin-4-ylmethyl)-piperazin-1yl) or piperazin 1-ylmethyl)-piperidin-1-yl)]-imidazo[2,1-b][1,3,4]thiadiazole derivatives and their use |
| 01/18/2012 | CN102325777A (+)-morphinananium n-oxides and processes for their production |
| 01/18/2012 | CN102325776A (+)-morphinanium quaternary salts and processes for their production |
| 01/18/2012 | CN102325775A (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
| 01/18/2012 | CN102325764A Pyrimidine indole derivatives for treating cancer |
| 01/18/2012 | CN102325755A Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds |
| 01/18/2012 | CN102325752A Carbazole and carboline kinase inhibitors |
| 01/18/2012 | CN102325549A Treatment of cancer with umanized anti-egfr igg1 antibody and irinotecan |
| 01/18/2012 | CN102325547A Anticancer composition comprising antitumor agent and substance having inhibitory effects on L1CAM activity and expression |
| 01/18/2012 | CN102325542A Compositions and methods to prevent cancer with cupredoxins |
| 01/18/2012 | CN102325529A Sigma(s) receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity |
| 01/18/2012 | CN102321760A Non-small cell lung cancer (NSCLC) marker and its application |
| 01/18/2012 | CN102321652A Dual expression vector of immunostimulatory RNA and liver cancer target gene Pim-3 silent RNA and application thereof |
| 01/18/2012 | CN102321635A Preparation method for human papillomaviral empty capsid particles, and products thereof |
| 01/18/2012 | CN102321626A Means for inhibiting the expression of protein kinase 3 |
| 01/18/2012 | CN102321625A Small molecular double stranded RNA group prepared from yeast, preparation method and use thereof |
| 01/18/2012 | CN102321579A Process for producing cytotoxic lymphocyte |
| 01/18/2012 | CN102321242A Polyethylene glycol-polylactic acid-poly-L-lysine copolymer, preparation method thereof and application thereof as gene or drug vector |
| 01/18/2012 | CN102321239A Preparation method of water-soluble toluylene compound prodrugs |
| 01/18/2012 | CN102321187A Method for extracting whole peptidoglycan from bifidobacterium longum NQ-1501 |
| 01/18/2012 | CN102321181A Cyclin D/CDK4 (Cyclin-Dependent Kinase) originated chimeric polypeptide with anti-tumor activity and application as anti-tumor medicament |
| 01/18/2012 | CN102321178A Novel gonadotropin releasing hormone oriented fusion protein mutant |
| 01/18/2012 | CN102321173A Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof |
| 01/18/2012 | CN102321159A Photosensitizer with tumor targeting and preparation method thereof |
| 01/18/2012 | CN102321158A Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| 01/18/2012 | CN102321156A Novel thymopentin compound and composition powder injection thereof |
| 01/18/2012 | CN102321144A Method for extracting ursolic acid from red jujube |
| 01/18/2012 | CN102321142A Abiraterone acetate crystal form and preparation method thereof |
| 01/18/2012 | CN102321134A Compound, preparation method and application |
| 01/18/2012 | CN102321133A Antibiotic Lobophorin E and F, preparation methods and applications thereof in preparing antibacterial and antitumor drugs |
| 01/18/2012 | CN102321096A Anticancer compound |
| 01/18/2012 | CN102321095A Chiral spiro indole-pyran pyridine alkaline compound and preparation and application thereof |
| 01/18/2012 | CN102321090A Chromene compound capable of inhibiting tumor angiogenesis and preparation method thereof |
| 01/18/2012 | CN102321077A Chromane substituted benzimidazoles and their use as acid pump inhibitors |
| 01/18/2012 | CN102321074A Indole ring-substituted pyrazole hydrazide derivative and preparation method and application thereof |
| 01/18/2012 | CN102321034A Sulfobenzodiazepine compound and application thereof used as medicament |
| 01/18/2012 | CN102321031A Polysubstituted 4, 6-distyryl pyrimidine compound and preparation method and application thereof |
| 01/18/2012 | CN102321030A Heterocyclic inhibitors of MEK and methods of use thereof |
| 01/18/2012 | CN102321012A Acenaphthene heterocyclic compounds and application thereof |
| 01/18/2012 | CN102320989A Uvaria macrophylla bisamide derivative and preparation method and application thereof |
| 01/18/2012 | CN102319439A Drug with magnetic microspheres, and use thereof |
| 01/18/2012 | CN102319438A Genistein clathrate compound-containing preparation and its preparation method and use |
| 01/18/2012 | CN102319437A Polymer conjugates of interferon-beta with enhanced biological potency |
| 01/18/2012 | CN102319436A Folic acid-modified O-carboxymethyl chitosan-deoxycholic acid complex and preparation method and application thereof |
| 01/18/2012 | CN102319434A Application of ultrasound in intelligent controlled release of medicament coated by temperature sensitive material |
| 01/18/2012 | CN102319430A Antibody formulations in histidine-acetate buffer |
| 01/18/2012 | CN102319426A Preparation method of specific tumor vaccine for removing regulatory T cells |
| 01/18/2012 | CN102319421A Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 01/18/2012 | CN102319419A Application of turtle peptide in pharmacy |